Published in Clinical Oncology Week, March 24th, 2008
"However, it is not clear whether rosiglitazone affects the protein expression of transforming growth factor 133 (TGF-beta 3) and the cell proliferation in human uterine leiomyoma cells in vitro. Human uterine leiomyoma tissues were dissected and cultured. Cells were divided into 5 groups: one control group and other four groups with different concentrations of rosiglitazone...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.